SOLICITATION NOTICE
B -- Conditional Olfm4 Custom Gene Knockout Services
- Notice Date
- 4/2/2015
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-HI-2015-106-CDB
- Archive Date
- 4/28/2015
- Point of Contact
- Chris Bocus, Phone: 3014027888
- E-Mail Address
-
chris.bocus@nih.gov
(chris.bocus@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- DESCRIPTION: (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. This acquisition is set aside for small businesses only. (ii) The solicitation number is HHS-NIH-NHLBI-CSB-HI-2015-106-CDB and the solicitation is issued as a request for proposal (RFP). Offerors shall submit their proposals no later than 3:00 p.m. Eastern Standard Time(EST) on Monday, April 13, 2015. (iii) The solicitation document, the incorporated provisions and clauses are those in the Federal Acquisition Circular 2005-80, effective March 2, 2015. (iv) The associated North American Industry Classification System (NAICS) code for this procurement is 325414 and the small business size standard is 500 employees. The acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13. PURPOSE: The purpose of this requirement is to procure custom gene knockout mice in the research of the role of Olfm4 in colon carcinogenesis. (v) Background: The mission of the NHLBI Division of Intramural Research (DIR) is to perform robust scientific and clinical research leading to a better understanding of biology and clinical pathology. To attain this goal, we have built a strong basic science foundation and coupled it closely with innovative technology development and outstanding clinical research both at the NIH Clinical Center and in partnership with local hospitals. The purview of our research is broad, encompassing investigations into the basic principles of molecular, cellular, and organ-level biology and their relationship to disease. Some current areas of fundamental interest include single molecule structure; protein assembly; molecular and cell biology; cell signaling and motility; membrane trafficking; physiology; systems biology; engineering and technology development. Insights into disease mechanisms derived from basic studies form the basis for translational research into new diagnostic and therapeutic approaches. DIR investigators also conduct concept-based clinical studies in the areas of interventional and surgical cardiology; pulmonary medicine; sickle cell anemia; bone marrow transplant; and hematologic disorders. Providing state-of-the-art training in basic, translational, and clinical research for the next generation of scientific and clinical leaders is a high priority. This program provides opportunities for scientists and trainees to work together towards a better understanding of molecular machines, the cell, the body, and ultimately the treatment of human diseases. The Molecular and Clinical Hematology Branch (MCHB) plans and conducts basic and clinical research on selected inherited and acquired diseases of human blood. The MCHB uses contemporary biochemical, molecular, and physiological techniques. It develops and validates models, including cellular and transgenic systems, to permit the delineation of regulatory mechanisms in normal and pathological hematopoiesis, and to facilitate pharmacological or molecular genetic approaches to correct or compensate for abnormalities associated with disease states. It also expedites the translation of novel basic scientific discovery to the appropriate level of preclinical or clinical investigation. The ultimate goal of the MCHB is to develop better approaches to diagnose, treat and eventually cure many congenital or acquired disorders of the bone marrow. An increased understanding of the molecular mechanisms controlling these events would increase our ability to combat selective cytopenias, and could facilitate hematopoietic reconstitution following radiation, chemotherapy, and marrow or peripheral stem cell transplantation. Also, leukemias and lymphomas are usually regarded as hematopoietic cells frozen at various stages of differentiation. Additional insights into the basic mechanism of the differentiation process are important to our understanding of leukemias and lymphomas. The laboratory requires the production of Olfm4/loxP mice for research studies. The Olfm4/loxP F1 mice will be used to cross with Cre-villin and Cre-lysozyme mice to produce intestinal epithelial cell and myeloid cell specific knock-out mice. These mice models will distinguish the tumor inhibitory effect of Olfm4 in myeloid cells, not in intestinal epithelial cells. The contractor will provide the following for the mOlfm4 conditional knockout: • Vector Construction • Correctly Targeted and Verified ES Cell Clones, ES Cell Injection Report, and Genotyping Report • Karyotype ES cells • Chimera mice creation • F1 heterozygote mice generation Contractor Requirements: • The project manager will report the progress of the project after each milestone step is finished. • The contractor must provide full gene targeting project as one that begins with vector construction and concludes with delivery of chimeras or germline F1 mutants. • The contractor must guarantee generation of specified mutant animals for all full gene targeting projects. • The contractor will deliver the vector (bacterial stab), all expanded and confirmed ES cell clones, and at least 2 germline F1 heterozygous mice to the government as the final products. • The contractor will deliver the vector (bacterial stab), all expanded and confirmed ES cell clones, and at least 3 male chimeras (each with >50% chimerism) to the government as the final products. Government requirements: • The government will provide information and instruction related to specific gene targeting • The government will perform polymerase chain reaction (PCR) to confirm that the mice have correct genotypes, i.e. the exon 4,5 of Olfm4 gene is floxed with loxP sites. (vi) Period of Performance: Delivery schedule will negotiated at award. (vii) The provision FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition and is hereby incorporated by reference. (viii) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition and is hereby incorporated by reference. Quotes will be evaluated in accordance with FAR 13.106. (ix) In accordance with FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items, Offerors must complete annual representations and certifications on-line at https://www.sam.gov/portal/public/SAM/. (x) FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items, applies to this acquisition. (xii) The Defense Priorities and Allocations System (DPAS) and assigned rating does not apply to this acquisition. Offerors shall submit their quotations no later than 3:00 p.m. Eastern Standard Time (EST) on Monday, April 13, 2015. The proposal must reference the RFP Number: HHS-NIH-NHLBI-CSB-HI-2015-106-CDB. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. This acquisition is set-aside for SMALL BUSINESSES. Proposals can be emailed to the Contract Specialist, Chris Bocus at chris.bocus@nih.gov; Quotations shall not be deemed received by the Government until the quotation is entered into the e-mail address inbox set forth above. Faxed proposals will NOT be accepted. All quotes shall contain the following: 1. Name of Contracting Organization; 2. Contract Number/RFP Number (for subcontracts, provide the prime contract number and the subcontract number); 3. Contract Type; 4. Total Contract Value and Discounts; 5. Description of Requirement; 6. Contracting Specialist's Name and Telephone Number; 7. North American Industry Classification System (NAICS) Code; and 8. DUNS Number.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-HI-2015-106-CDB/listing.html)
- Place of Performance
- Address: Contractor's Address, United States
- Record
- SN03687235-W 20150404/150402235918-6ef9550247480b54f30a4599b2012749 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |